milosh, market expecting the QR should be better than previous QR. Revenue is maintain but profit margin did not increase.Market tomorrow may have jitter sell

https://www.klsescreener.com/v2/news/view/840631
丹麦也有“网红股” Orphazyme无故飙近14倍
Nanyang Sun, Jun 13, 2021 12:13am - 12 hours ago


（哥本哈根12日讯）丹麦的投资者和分析师整个上午都在思索，一家小型生物技术公司为何突然在隔夜美国交易时段飙升近1400%。

Orphazyme A/S称，不知道为何其美国存托股票隔夜飙升。公司周五在哥本哈根开盘后，股价最初一度上涨76%，美国开盘后飙升超过140%。

该公司警告投资者不要参与这股狂潮。

Aluminum Futures - (MALTRc1)

Real-time derived

Create Alert
Add to Portfolio
2,413.75 +30.75 +1.29%

Alcom posted PBT 10 m, good result.Thursday will impact LBALUM also

Hi Luckyboy88 , no need to worry so much of LBALUM. If u look at the past 10 years QR result, u will notice only 1 QR having -ve result. It mean the management no hanky-panky. Properly report the earning.Last QR 144M Revenue, the next QR with Aluminium price increase,profit will definitely jump. It just matter of time, it will above RM2.40, PE8-10, if every QR 15 million profit.

MA60, the support at 0.85 sen

It seem someone is keep selling at 960. Very persistent. Like big shareholder.

I also cut loss, sad.Big hammer candle today, today whoever bought all loser,monday will have pressure

Hi roger3210, highly QR result fail. Haha

Aluminum Futures - (MALTRc1)

Real-time derived

Create Alert
Add to Portfolio
2,511.25 +64.25 +2.63%
14:00:03 - Closed.

Aluminum Futures - (MALTRc1)

Real-time derived

Create Alert
Add to Portfolio
2,511.25 +64.25 +2.63%
14:00:03 - Closed.

Hi roger3210, I agreed with u.But PA need to be careful as First Solar in US, the result out big drop until now due to materials cost increase.PA contract with first solar, may have loss also as the material cost increase.

Sorry rebounce with high volume as LBALUM.

Hi roger3210, Alcom SMA 20 is 109, it has break since yesterday, technically within 3 days must re bounce as LBALUM with last volume,otherwise need to watch out as QR coming soon.

Soybean Futures,Jul-2021 (ZS=F)
CBOT - CBOT Delayed Price. Currency in USX
Add to watchlist

Quote Lookup

1,498.25+1.00 (+0.07%)
As of 2:19PM EDT. Market open.

Suyabean record high

Soybean Futures,Jul-2021 (ZS=F)
CBOT - CBOT Delayed Price. Currency in USX
Add to watchlist

Quote Lookup

1,498.25+1.00 (+0.07%)
As of 2:19PM EDT. Market open.

Suyabean record high

Soybean Futures,Jul-2021 (ZS=F)
CBOT - CBOT Delayed Price. Currency in USX
Add to watchlist

Quote Lookup

1,498.25+1.00 (+0.07%)
As of 2:19PM EDT. Market open.

Suyabean record high

Aluminum Futures - (MALTRc1)

Real-time derived

Create Alert
Add to Portfolio
2,364.50 +51.25 +2.22%

Today Fly

Aluminum Futures - (MALTRc1)

Real-time derived

Create Alert
Add to Portfolio
2,364.50 +51.25 +2.22%

Today Should back to Rm1.30

Not too b so worry, Supermax RSI 6 - 6%. Not much room to down already. The recent selloff could b margin call selloff. If rebounce, should have 10-15% margin.

Standard Life Aberdeen plc, is a United Kingdom-based global investment company headquartered in Edinburgh, Scotland. In March 2017, Standard Life reached an agreement to merge with the investment company Aberdeen Asset Management. Standard Life was renamed Standard Life Aberdeen on 14 August 2017. Wikipedia
Assets under management: 544.6 billion GBP (2019)
CEO: Stephen Bird (Sep 1, 2020–)
Headquarters: Edinburgh, United Kingdom
Revenue: 1.634 billion GBP (2019)
Number of employees: 9,651 (2019)
Subsidiaries: HDFC Life Insurance, Aberdeen Asset Management,

CanSino Biologics Inc. (6185.HK)
HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist

Quote Lookup

299.200+46.800 (+18.54%)
As of 3:00PM HKT. Market open.

GoodBoy Bro,
May I know how you get the below RSS info?

RSS sold volumes for today from 9:00 am to 12:30 pm ... Kossan 0 shares, Hartalega 168,400 shares, TopGlove 1,189,300 shares, SuperMax 275,000 shares ...

https://www.theedgemarkets.com/article/apex-healthcare-ready-play-role-vaccine-distribution

LiimInvest u r right,but Apex very expensive, the market cap 1.7B almost like Pharma

https://www.theedgemarkets.com/article/sinopharm-jvco-sponsor-10000-doses-covid19-vaccine-front-liners?type=malaysia

Good News. Tomorrow all vaccine stocks jump. Glove stocks down

https://www.theedgemarkets.com/article/sinopharm-jvco-sponsor-10000-doses-covid19-vaccine-front-liners?type=malaysia

This mean GG liao? Sinopharm vaccine go to Mashing?Tan Sri Leong Hoy Kum (Mashing boss)? Dpharma & Pharma also GG?

https://www.theedgemarkets.com/article/sinopharm-jvco-sponsor-10000-doses-covid19-vaccine-front-liners?type=malaysia

This mean GG liao? Sinopharm vaccine go to Mashing?Tan Sri Leong Hoy Kum (Mashing boss)? Dpharma & Pharma also GG?

Monsoon 11/11, really come. CPO price continue up

https://www.chinapress.com.my/20201109/%e4%b8%9c%e5%8c%97%e5%ad%a3%e5%80%99%e9%a3%8e-1111%e6%9d%80%e5%88%b0%ef%bc%81-%e6%96%99%e6%8c%81%e7%bb%ad%e8%87%b3%e6%98%8e%e5%b9%b43%e6%9c%88/

https://www.washingtonpost.com/nation/2020/09/03/coronavirus-covid-live-updates-us/

The Centers for Disease Control and Prevention is telling state health officials to be ready to distribute a coronavirus vaccine to health-care workers and other high-priority groups as soon as Nov. 1, heightening fears that the agency is under pressure to approve a vaccine before Election Day. Some scientists warn that granting emergency authorization to a vaccine before clinical trials are complete could pose safety dangers and inflame anti-vaccination sentiment — but others say that doing so could save thousands of lives.

http://www.pharmcube.com/news/article/5367?index=news
10 康希诺（中国）资金：N/A
临床进展：Phase I/II：II期结果显示，单针免疫后，绝大多数受试者体内激发了显著的免疫反应。Phase III：即将在俄罗斯、巴西、智利和菲律宾招募40000名志愿者进行试验这是中国首个进入临床试验的新冠疫苗，也是国内首个获得军队特需药品批件的新冠疫苗，有效期一年。这款由康希诺与陈薇院士团队合作开发的腺病毒载体疫苗，已在6月份完成了II期临床研究，研究结果显示，该疫苗能够诱导人体产生特异性抗体，具有较好的有效性和安全性。目前该公司正在准备与多国携手启动III期临床试验，拟计划在沙特的利雅得、达曼和麦加3个主要城市招募5000名18岁以上健康志愿者进行试验。预计到2021年初可生产1~2亿剂疫苗。

10 Can Sino (China) Funding: N/A
Clinical progress: Phase I/II: Phase II results showed that after a single injection, most subjects stimulated a significant immune response. Phase III: 40,000 volunteers will be recruited for trials in Russia, Brazil, Chile, and the Philippines. This is China's first COVID-19 vaccine to enter clinical trials and the first domestic COVID-19 vaccine to be approved for military special needs. The validity period is one year. This adenovirus vector vaccine, developed in cooperation with the team of Cansino and Academician Chen Wei, has completed a phase II clinical study in June. The research results show that the vaccine can induce the human body to produce specific antibodies and has good effectiveness and safety. The company is currently preparing to start phase III clinical trials with many countries. It plans to recruit 5,000 healthy volunteers over 18 years of age in three major cities in Saudi Arabia, Riyadh, Dammam and Mecca. It is estimated that 100 to 200 million doses of vaccine can be produced by early 2021.